Cargando…
20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways
Osteolysis is a principal reason for arthroplasty failure like aseptic loosening induced by Titanium (Ti) particle. It is a challenge for orthopedic surgeons. Recent researches show that 20(S)-protopanaxadiol can inhibit inflammatory cytokine release in vitro. This study aims to assess the effect of...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345703/ https://www.ncbi.nlm.nih.gov/pubmed/30713497 http://dx.doi.org/10.3389/fphar.2018.01538 |
_version_ | 1783389604775198720 |
---|---|
author | Pan, Chenhao Shan, Haojie Wu, Tianyi Liu, Wei Lin, Yiwei Xia, Wenyang Wang, Feng Zhou, Zubin Yu, Xiaowei |
author_facet | Pan, Chenhao Shan, Haojie Wu, Tianyi Liu, Wei Lin, Yiwei Xia, Wenyang Wang, Feng Zhou, Zubin Yu, Xiaowei |
author_sort | Pan, Chenhao |
collection | PubMed |
description | Osteolysis is a principal reason for arthroplasty failure like aseptic loosening induced by Titanium (Ti) particle. It is a challenge for orthopedic surgeons. Recent researches show that 20(S)-protopanaxadiol can inhibit inflammatory cytokine release in vitro. This study aims to assess the effect of 20(S)-protopanaxadiol on Ti particle-induced osteolysis and RANKL-mediated osteoclastogenesis. Micro-CT and histological analysis in vivo indicated the inhibitory effects of 20(S)-protopanaxadiol on osteoclastogenesis and the excretion of inflammatory cytokines. Next, we demonstrated that 20(S)-protopanaxadiol inhibited osteoclast differentiation, bone resorption area, and F-actin ring formation in a dose-dependent manner. Moreover, mechanistic studies suggested that the suppression of MAPK and NF-κB signaling pathways were found to mediate the inhibitory effects of 20(S)-protopanaxadiol. In conclusion, 20(S)-protopanaxadiol may suppress osteoclastogenesis in a dose- dependent manner and it could be a potential treatment of Ti particle-induced osteolysis. |
format | Online Article Text |
id | pubmed-6345703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63457032019-02-01 20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways Pan, Chenhao Shan, Haojie Wu, Tianyi Liu, Wei Lin, Yiwei Xia, Wenyang Wang, Feng Zhou, Zubin Yu, Xiaowei Front Pharmacol Pharmacology Osteolysis is a principal reason for arthroplasty failure like aseptic loosening induced by Titanium (Ti) particle. It is a challenge for orthopedic surgeons. Recent researches show that 20(S)-protopanaxadiol can inhibit inflammatory cytokine release in vitro. This study aims to assess the effect of 20(S)-protopanaxadiol on Ti particle-induced osteolysis and RANKL-mediated osteoclastogenesis. Micro-CT and histological analysis in vivo indicated the inhibitory effects of 20(S)-protopanaxadiol on osteoclastogenesis and the excretion of inflammatory cytokines. Next, we demonstrated that 20(S)-protopanaxadiol inhibited osteoclast differentiation, bone resorption area, and F-actin ring formation in a dose-dependent manner. Moreover, mechanistic studies suggested that the suppression of MAPK and NF-κB signaling pathways were found to mediate the inhibitory effects of 20(S)-protopanaxadiol. In conclusion, 20(S)-protopanaxadiol may suppress osteoclastogenesis in a dose- dependent manner and it could be a potential treatment of Ti particle-induced osteolysis. Frontiers Media S.A. 2019-01-18 /pmc/articles/PMC6345703/ /pubmed/30713497 http://dx.doi.org/10.3389/fphar.2018.01538 Text en Copyright © 2019 Pan, Shan, Wu, Liu, Lin, Xia, Wang, Zhou and Yu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Pan, Chenhao Shan, Haojie Wu, Tianyi Liu, Wei Lin, Yiwei Xia, Wenyang Wang, Feng Zhou, Zubin Yu, Xiaowei 20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways |
title | 20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways |
title_full | 20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways |
title_fullStr | 20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways |
title_full_unstemmed | 20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways |
title_short | 20(S)-Protopanaxadiol Inhibits Titanium Particle-Induced Inflammatory Osteolysis and RANKL-Mediated Osteoclastogenesis via MAPK and NF-κB Signaling Pathways |
title_sort | 20(s)-protopanaxadiol inhibits titanium particle-induced inflammatory osteolysis and rankl-mediated osteoclastogenesis via mapk and nf-κb signaling pathways |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345703/ https://www.ncbi.nlm.nih.gov/pubmed/30713497 http://dx.doi.org/10.3389/fphar.2018.01538 |
work_keys_str_mv | AT panchenhao 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways AT shanhaojie 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways AT wutianyi 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways AT liuwei 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways AT linyiwei 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways AT xiawenyang 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways AT wangfeng 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways AT zhouzubin 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways AT yuxiaowei 20sprotopanaxadiolinhibitstitaniumparticleinducedinflammatoryosteolysisandranklmediatedosteoclastogenesisviamapkandnfkbsignalingpathways |